<div id="readability-page-1"><div><div><table><tbody><tr><td><span>Reporter Name</span></td><td><span>Urist Marshall</span></td></tr><tr><td><span>Relationship</span></td><td><span>EVP, Research &amp; Investments, 10% Owner</span></td></tr><tr><td><span>Type</span></td><td><span>Sell</span></td></tr><tr><td><span>Amount</span></td><td><span>$1,627,814</span></td></tr><tr><td><span>SEC Filing</span></td><td>Form 4</td></tr></tbody></table></div><p><span>Urist Marshall, EVP of Research &amp; Investments at Royalty Pharma plc and a 10% owner, sold 41,576 Class A Ordinary Shares for a total of $1,627,814. The transactions, conducted on December 5, 2025, were executed at weighted average prices of $39.1528 and $39.1527 for two separate sales. Following these transactions, Marshall directly owns 7,398 shares and indirectly owns 179,020 shares through Sandy Lamm LLC and an IRA. The sales were made under a 10b5-1 plan adopted on August 29, 2025.</span></p><p><span>SEC Filing: </span>Royalty Pharma plc [ RPRX ] - Form 4 - Dec. 09, 2025</p></div></div>

RPRX

<p>Royalty Pharma's EVP, Urist Marshall, sold 41,576 Class A Ordinary Shares totaling $1,627,814 on December 5, 2025. The sales were executed at average prices of $39.1528 and $39.1527. Marshall now directly owns 7,398 shares and indirectly owns 179,020 shares. The transactions were made under a 10b5-1 plan adopted on August 29, 2025.</p>

Royalty Pharma EVP Sells Over $1.6 Million in Shares